Search Orphan Drug Designations and Approvals
-
Generic Name: | antisense 20-mer phosphorothioate oligonucleotide [complementary to the coding region of R2 component of the human ribonucleotide reductase mRNA] |
---|---|
Date Designated: | 03/12/2003 |
Orphan Designation: | Treatment for renal cell carcinoma |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Lorus Therapeutics, Inc 2 Meridan Road Toronto Canada The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-